SatoshiShojiMD, PhDa?ToshikiKunoMD, PhDb?TomohiroFujisakiMDcHisatoTakagiMD, PhDdAlexandrosBriasoulisMD, PhDePierreDeharoMDfghThomasCuissetMD, PhDfghAzeemLatibMDiShunKohsakaMD, PhDa
doi : 10.1016/j.jacc.2021.06.012
Volume 78, Issue 8, 24 August 2021, Pages 763-777
Balancing the effects of dual antiplatelet therapy (DAPT) in the era of potent P2Y12 inhibitors has become a cornerstone of acute coronary syndrome (ACS) management. Recent randomized controlled trials (RCTs) have investigated DAPT de-escalation to decrease the risk of bleeding outcomes.
Kwan S.LeeMDArkaChatterjeeMDDeepakAcharyaMD
doi : 10.1016/j.jacc.2021.06.030
Volume 78, Issue 8, 24 August 2021, Pages 778-780
Johannes T.NeumannMD, MCRabcJessicaWeimannMScaNils A.S?rensenMDabTau S.HartikainenMDaPaul M.HallerMD, PhDabJonasLehmacherMDaCelineBrocksaSophiaTenhaeffaMahirKarakasMD, PhDabThomasRennéPhDdStefanBlankenbergMDabTanjaZellerPhDabDirkWestermannMDab
doi : 10.1016/j.jacc.2021.06.027
Volume 78, Issue 8, 24 August 2021, Pages 781-790
Discrimination among patients with type 1 myocardial infarction (T1MI), type 2 myocardial infarction (T2MI), and myocardial injury is difficult.
James L.JanuzziJr.MDabCian P.McCarthyMB, BCh, BAOa
doi : 10.1016/j.jacc.2021.06.026
Volume 78, Issue 8, 24 August 2021, Pages 791-793
Javier A.ValleMD, MSCSabcZhuokaiLiPhDdAndrzej S.KosinskiPhDdAdam J.NelsonMBBS, PhDdSreekanthVemulapalliMDdeJosephClevelandMDbDavidFullertonMDbJohn C.MessengerMDbJessica Y.RoveMDbRory S.BrickerMDbSteven M.BradleyMD, MPHfFrederick A.MasoudiMD, MSPHbRobert W.YehMD, MSc, MBAgEhrin J.ArmstrongMD, MScabStephen W.WaldoMDabJohn D.CarrollMDb
doi : 10.1016/j.jacc.2021.06.028
Volume 78, Issue 8, 24 August 2021, Pages 794-806
Societal guidelines and payor coverage decisions for transcatheter aortic valve replacement (TAVR) attempt to strike a balance between providing access and maintaining quality. The extent to which dissemination of TAVR has achieved these ideals remains unknown.
David R.HolmesJr.MDaD. CraigMillerMDb
doi : 10.1016/j.jacc.2021.07.008
Volume 78, Issue 8, 24 August 2021, Pages 807-810
WissamAlajajiMDaJohn M.HornickMDaElianeMalekMDbAllan L.KleinMDc
doi : 10.1016/j.jacc.2021.06.023
Volume 78, Issue 8, 24 August 2021, Pages 811-824
There is a lack of knowledge in the current medical literature about native aortic valve thrombosis.
Jose Luis ZamoranoG?mezMD, PhDAriana Gonz?lezG?mezMD
doi : 10.1016/j.jacc.2021.06.025
Volume 78, Issue 8, 24 August 2021, Pages 825-826
Stuart J.PocockPhDabXavierRosselloPhDabRuthOwenMScaTim J.CollierMScaGregg W.StoneMDcFrank W.RockholdPhDd
doi : 10.1016/j.jacc.2021.06.024
Volume 78, Issue 8, 24 August 2021, Pages 827-839
Consensus as to best practices for the selection, reporting, and interpretation of primary and secondary outcomes of randomized controlled trials is lacking. We reviewed the strategies adopted in publications of randomized controlled trials (RCTs) for the analysis, presentation, and interpretation of efficacy outcomes from a survey of all cardiovascular RCTs published in the New England Journal of Medicine, Lancet, and the Journal of the American Medical Association during 2019. We focus on the choice of primary outcomes, the variety of approaches to selecting secondary outcomes, the options sometimes used to control type I error, and the common practice to not correct for multiple testing in reporting secondary outcomes. We comment on current practice across journals in the reporting of P values and also how conclusions in trial reports frequently adhere to an undue reliance on P < 0.05 as a basis for positive claims of treatment efficacy. We conclude with recommendations for how future RCT reports could best select, report, and interpret their findings on primary and secondary outcomes.
Eugene B.WuMDaEmmanouil S.BrilakisMD, PhDbKambisMashayekhiMDcEtsuoTsuchikaneMD, PhDdKhaldoonAlaswadMDeMarioArayaMDfAlexandreAvranMDgLorenzoAzzaliniMD, MSc, PhDhAvtandil M.BabunashviliMDiBaktashBayaniMDjMichaelBehnesMDkRavinayBhindiMDlNicolasBoudouMDmMarouaneBoukhrisMDnNenad Z.BozinovicMDoLeszekBryniarskiMDpAlexanderBufeMDqChristopher E.BullerMDrsM. NicholasBurkeMDbAchimButtnerMDsPedroCardosoMDtMauroCarlinoMDuJi-YanChenMDvEvald HoejChristiansenMDwAntonioColomboMDxKevinCroceMD, PhDyFelix Damasde los SantosMD, METzTonyde MartiniMDaaJosephDensMD, PhDbbCarlodi MarioMDccKefeiDouMDddMohanedEgredMDeeBasemElbarouniMDffAhmed M.ElGuindyMDggJavierEscanedMDhhSergeyFurkaloMDiiAndreaGagnorMDjjAlfredo R.GalassiMDkkRobertoGarboMDllGabrieleGaspariniMDmmJunboGeMDnnLeiGeMDnnPravin KumarGoelMDooOmerGoktekinMDppNievesGonzaloMDqqLucaGranciniMDrrAllisonHallMDssFranklin LeonardoHanna QuesadaMDttColmHanrattyMDuuStefanHarbMDvvScott A.HardingMDwwRajaHatemMDxxJose P.S.HenriquesMDyyDavidHildick-SmithMDzzJonathan M.HillMDaaaAngelaHoyeMDbbbWissamJaberMDcccFarouc A.JafferMD, PhDdddYangsooJangMDeeeRistoJussilaMDfffArtisKalninsMDgggArunKalyanasundaramMD, MPHhhhDavid E.KandzariMDiiiHsien-LiKaoMDjjjDimitriKarmpaliotisMD, PhDkkkHussien HeshmatKassemMD, PhDlllJaikirshanKhatriMDmmmPaulKnaapenMDnnnRanKornowskiMDoooOlegKrestyaninovMDpppA.V. GaneshKumarMDqqqPablo ManuelLamelasMD, MScrrrSeung-WhanLeeMDsssThierryLefevreMDtttRaymondLeungMDuuuYuLiMDvvvYueLiMDwwwSoo-TeikLimMDxxxSidneyLoMDyyyWilliamLombardiMDzzzAnbukarasiMaranMDaaaaMargaretMcEntegartMD, PhDbbbbJeffreyMosesMDccccMuhammadMunawarMDddddAndresNavarroMDeeeeHung M.NgoMD, PhDffffWilliamNicholsonMDggggAnjaOksnesMDhhhhGoran K.OlivecronaMD, PhDiiiiLucioPadillaMDjjjjMitulPatelMDkkkkAshishPershadMDllllMarinPostuMDmmmmJieQianMDnnnnAlexandreQuadrosMDooooNidal AbiRafehMDppppTrulsR?munddalMD, PhDqqqqVithala SuryaPrakasa RaoMDrrrrNicolausReifartMD, PhDssssRobert F.RileyMDttttStephaneRinfretMDuuuuMeruzhanSaghatelyanMDvvvvGeorgeSianosMD, PhDwwwwElliotSmithMDxxxxAnthonySpaedyMDyyyyJamesSprattMDzzzzGreggStoneMDaaaaaJulian W.StrangeMDbbbbbKhalid O.TammamMD, PhDcccccCraig A.ThompsonMDdddddAurelTomaMDeeeeeJennifer A.TremmelMD, MSfffffRicardo SantiagoTrinidadMDgggggImreUngiMD, PhDhhhhhMinhVoMDiiiiiVu HoangVuMDjjjjjSimonWalshMDuuGeraldWernerMDkkkkkJaroslawWojcikMDlllllJasonWollmuthMDmmmmmBoXuMDnnnnnMasahisaYamaneMDoooooLuiz F.YbarraMDpppppRobert W.YehMDqqqqqQiZhangMDrrrrr
doi : 10.1016/j.jacc.2021.05.055
Volume 78, Issue 8, 24 August 2021, Pages 840-853
The authors developed a global chronic total occlusion crossing algorithm following 10 steps: 1) dual angiography; 2) careful angiographic review focusing on proximal cap morphology, occlusion segment, distal vessel quality, and collateral circulation; 3) approaching proximal cap ambiguity using intravascular ultrasound, retrograde, and move-the-cap techniques; 4) approaching poor distal vessel quality using the retrograde approach and bifurcation at the distal cap by use of a dual-lumen catheter and intravascular ultrasound; 5) feasibility of retrograde crossing through grafts and septal and epicardial collateral vessels; 6) antegrade wiring strategies; 7) retrograde approach; 8) changing strategy when failing to achieve progress; 9) considering performing an investment procedure if crossing attempts fail; and 10) stopping when reaching high radiation or contrast dose or in case of long procedural time, occurrence of a serious complication, operator and patient fatigue, or lack of expertise or equipment. This algorithm can improve outcomes and expand discussion, research, and collaboration.
Kiarri N.KershawPhDJaneRaffertyMALucia C.PetitoPhDSadiya S.KhanMD
doi : 10.1016/j.jacc.2021.06.029
Volume 78, Issue 8, 24 August 2021, Pages 854-855
TakenoriIkomaMDHidekiSaitoMDToshiakiOkaMD, PhDYuichiroMaekawaMD, PhD
doi : 10.1016/j.jacc.2021.06.013
Volume 78, Issue 8, 24 August 2021, Pages 855-856
LaraHersbergerMDZenoStangaMDPhilippSchuetzMD, MPH
doi : 10.1016/j.jacc.2021.06.015
Volume 78, Issue 8, 24 August 2021, Pages 856-857
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟